GoodRx Holdings, Inc. reported a decline in financial performance for the first quarter of 2026, with total revenue decreasing to $194.0 million from $202.9 million in the same period of 2025. The company's net income also fell significantly, dropping to $1.2 million, or $0.00 per share, compared to $11.1 million, or $0.03 per share, in the prior year. The decrease in revenue was primarily attributed to a 24% decline in prescription transactions revenue, which fell to $113.7 million, driven by a reduction in Monthly Active Consumers and broader changes in the retail pharmacy landscape, including store closures.

In terms of operational metrics, GoodRx reported 5.3 million Monthly Active Consumers for the quarter, a decrease from 6.4 million in the same quarter last year. The company also saw an increase in subscription revenue, which rose 16% year-over-year to $24.4 million, supported by the introduction of new condition-specific subscription programs. Additionally, Pharma Direct revenue surged by 82% to $52.2 million, reflecting the company's efforts to expand its market penetration with pharmaceutical manufacturers.

GoodRx's total operating expenses remained relatively stable at $180.0 million, with notable increases in the cost of revenue, which rose by 51% to $20.2 million, largely due to higher prescription delivery and fulfillment costs. The company also reported a decrease in general and administrative expenses, which fell by 9% to $26.8 million, partly due to a prior impairment loss related to leased office space. Despite these cost management efforts, the overall operating income decreased to $14.0 million from $23.4 million in the previous year.

Looking ahead, GoodRx remains focused on strategic initiatives to enhance its offerings and market position. The company recently launched Employer Direct, a platform aimed at helping employers provide integrated cash pricing for their employees. GoodRx is also adapting to the evolving healthcare landscape, which includes increased demand for pricing transparency and affordability solutions. The company anticipates that while the transition to new business models may impact short-term financial performance, it will ultimately enhance long-term growth prospects. As of March 31, 2026, GoodRx had cash and cash equivalents of $235.7 million and no borrowings against its revolving credit facility, positioning it well for future investments and operational needs.

About GoodRx Holdings, Inc.

GoodRx Holdings, Inc. operates a digital healthcare platform providing price transparency and savings solutions for prescription medications in the U.S. It offers price comparison tools, subscription plans, telehealth services, and pharma manufacturer solutions, serving consumers, healthcare providers, pharmacies, PBMs, and pharma companies. The company's value lies in improving medication affordability, adherence, and access through proprietary technology, industry partnerships, and data-driven insights.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.